Microbix Biosystems Inc.
TSX : MBX

Microbix Biosystems Inc.

June 09, 2015 08:32 ET

Microbix Launches Two New Antigens to Diagnose Toxoplasma Gondii

Improves Performance and Cost of Diagnostic Testing

TORONTO, ONTARIO--(Marketwired - June 9, 2015) - Microbix Biosystems Inc. (TSX:MBX), an innovator of biological products and technologies, and manufacturer of the world's largest line of native infectious disease antigens, today announced the commercial introduction of two new Toxoplasma Gondii products targeted at immunoassay manufacturers looking for improved sensitivity and specificity of diagnostic tests.

Toxoplasma is a common parasitic infection spread primarily by cats and contaminated food. While toxoplasma infection is usually asymptomatic in healthy people, it can cause serious complications to a developing fetus and to the immune compromised (e.g. HIV infected patients). Toxoplasma testing is part of the TORCH diagnostic panel (Toxoplasma, Rubella, CMV, Herpes) routinely administered to expectant mothers in the first trimester of pregnancy.

The new antigens available from Microbix will be used in IgG and IgM antibody detection tests produced by most of the world's leading diagnostic manufacturers. Many of these companies already use antigens produced by Microbix.

"Microbix is the #1 supplier of Rubella and CMV in the world, so adding Toxoplasma antigen is a natural fit as most of our current customers also produce assays for the detection of the Toxoplasma antibody," said Phil Casselli, Microbix' Senior Vice President of Business Development, Marketing and Sales.

About Microbix

Microbix Biosystems Inc. specializes in the research and development of biological solutions, including products for human health applications, namely in the vaccine, therapeutic and diagnostic markets, as well as animal reproductive markets worldwide. The Company manufactures and distributes a wide range of infectious disease antigens to a worldwide customer base. The Company's pipeline of innovative technologies and products includes LumiSort™ semen sexing technology for the livestock industries, Kinlytic®, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots, and VIRUSMAX®, a proprietary technology for increasing virus yields in the manufacture of influenza vaccine. Established in 1988, Microbix is a publicly traded company, listed on the Toronto Stock Exchange, and headquartered in Mississauga, Ontario.

Forward-Looking Information

This news release includes "forward-looking information", as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, the risks associated with development projects, operations in foreign jurisdictions, risks associated with engineering and construction generally, risks associated with production including control over costs, quality, quantity and timeliness of delivery of products, foreign currency and exchange rate risk, and risks of raising capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company's judgment as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.

Please visit www.sedar.com for recent Microbix Biosystems Inc. filings.

For further information, please visit www.microbix.com.

Contact Information